SLC5A2 and COVID-19: The SGLT-2 inhibitors and metformin group had a lower incidence of SARS-Cov-2 infections, COVID-19 hospitalizations, and COVID-19 deaths compared to SGLT-2 and metformin nonusers, respectively.